KB-1189

Monalizumab

Background

CD94/NKG2A heterodimer is a type II transmembrane receptor that belongs to the C-type lectin family containing a single intracellular ITIM domain that recognizes HLA-E, a nonclassical HLA-I molecule. NKG2A participates in NK cell-mediated self-tolerance upon binding to HLA-E, which in turn has been related to tumor evasion in a wide variety of solid tumors and hematological malignancies, such as MM . Monalizumab is a humanized IgG4 antibody that abrogates NKG2A inhibitory function by impeding its interaction with HLA-E. This mAb has already shown promising results in head and neck squamous cell carcinoma (in combination with cetuximab) and gynecological cancers in phase II clinical trials.

Specifications

Catalog Number:
KB-1189
Cell Line Name:
Monalizumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
NKG2A
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1.Van Montfoort N, Borst L, Korrer MJ, Sluijter M, Marijt KA, Santegoets SJ, van Ham VJ, Ehsan I, Charoentong P, Andre P, et al. NKG2A blockade potentiates CD8 T cell immunity induced by Cancer vaccines. Cell. 2018;175(7):1744–55 e1715. 2.Andre P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Blery M, Bonnafous C, Gauthier L, Morel A, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175(7):1731–43 e1713. 3.Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391:795–9.
Please enable JavaScript in your browser to complete this form.